Cigna Group's (CI) Outperform Rating Reaffirmed at Royal Bank Of Canada

Key Points

• Royal Bank of Canada reaffirmed its “outperform” rating on Cigna, with a $337 price target implying approximately 27.3% upside from the reported $264.68 share price. Analysts overall maintain a “Moderate Buy” consensus, with a $337.10 average target.
• Cigna exceeded quarterly expectations, reporting $7.78 in earnings per share versus the $7.60 consensus and $71.56 billion in revenue versus $70.14 billion expected. Revenue increased 6.7% year over year, while the company reaffirmed fiscal 2026 adjusted EPS guidance of about $30.45.
• The company is pursuing long-term growth through its “Lead to One” strategy, specialty pharmacy and complex-care expansion, and a planned $3 billion modernization initiative; however, its $280 billion revenue guidance is below the $287.2 billion analyst estimate.

Cigna Group (NYSE:CI - Get Free Report)'s stock had its "outperform" rating reissued by Royal Bank Of Canada in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $337.00 price target on the health services provider's stock. Royal Bank Of Canada's target price would suggest a potential upside of 27.33% from the stock's current price.

A number of other brokerages have also weighed in on CI. Wells Fargo & Company upped their target price on Cigna Group from $305.00 to $307.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Sanford C. Bernstein upped their target price on Cigna Group from $371.00 to $381.00 and gave the stock an "outperform" rating in a research note on Thursday, July 9th. Jefferies Financial Group lowered Cigna Group from a "buy" rating to a "hold" rating and decreased their target price for the stock from $336.00 to $307.00 in a research note on Tuesday, August 4th. Piper Sandler decreased their target price on Cigna Group from $370.00 to $346.00 and set an "overweight" rating on the stock in a research note on Wednesday, June 3rd. Finally, Wolfe Research reiterated an "outperform" rating and issued a $315.00 price objective on shares of Cigna Group in a report on Tuesday, June 16th. Fifteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat, Cigna Group presently has an average rating of "Moderate Buy" and a consensus price target of $337.10.

Cigna Group Price Performance

CI traded down $7.16 during trading on Thursday, reaching $264.68. 109,818 shares of the company were exchanged, compared to its average volume of 1,674,385. The company's 50-day moving average is $279.53 and its two-hundred day moving average is $280.55. The company has a market cap of $69.94 billion, a price-to-earnings ratio of 10.94, a P/E/G ratio of 0.93 and a beta of 0.31. The company has a quick ratio of 0.76, a current ratio of 0.76 and a debt-to-equity ratio of 0.68. Cigna Group has a 12-month low of $239.51 and a 12-month high of $315.47.

Cigna Group (NYSE:CI - Get Free Report) last announced its earnings results on Thursday, July 30th. The health services provider reported $7.78 earnings per share for the quarter, topping analysts' consensus estimates of $7.60 by $0.18. The business had revenue of $71.56 billion for the quarter, compared to analyst estimates of $70.14 billion. Cigna Group had a return on equity of 19.75% and a net margin of 2.27%.The company's quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the company earned $7.20 EPS. Cigna Group has set its FY 2026 guidance at 30.450- EPS. Research analysts forecast that Cigna Group will post 30.51 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Everett Neville sold 617 shares of the stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $284.05, for a total transaction of $175,258.85. Following the completion of the sale, the insider directly owned 5,053 shares in the company, valued at $1,435,304.65. This represents a 10.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Nicole Jones sold 2,677 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $279.61, for a total value of $748,515.97. Following the sale, the insider owned 25,880 shares of the company's stock, valued at $7,236,306.80. This represents a 9.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 22,730 shares of company stock valued at $6,293,359 over the last 90 days. 0.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cigna Group

Institutional investors and hedge funds have recently bought and sold shares of the business. Osbon Capital Management LLC purchased a new stake in Cigna Group in the 2nd quarter worth approximately $26,000. Johnson Financial Group Inc. purchased a new stake in Cigna Group in the 2nd quarter worth approximately $29,000. Fiduciary Financial Advisors purchased a new stake in Cigna Group in the 2nd quarter worth approximately $29,000. Cedar Mountain Advisors LLC lifted its holdings in Cigna Group by 161.9% in the 1st quarter. Cedar Mountain Advisors LLC now owns 110 shares of the health services provider's stock worth $29,000 after buying an additional 68 shares during the period. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in Cigna Group in the 2nd quarter worth approximately $34,000. Hedge funds and other institutional investors own 86.99% of the company's stock.

Key Stories Impacting Cigna Group

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Cigna introduced its “Lead to One” strategy, emphasizing personalized care, clinical expertise, data and artificial intelligence. Management expects these capabilities to support a 10%–14% adjusted EPS compound annual growth rate through 2030, providing a new long-term framework for investors. The Cigna Group Hosts 2026 Investor Day
• Positive Sentiment: The company plans to invest $3 billion in a multiyear modernization and productivity initiative designed to improve workflows, lower operating friction and strengthen performance. Although the spending could weigh on near-term results, investors may view it as support for longer-term margin and earnings growth. Cigna to invest $3 billion in a multiyear initiative
• Positive Sentiment: New CEO Brian Evanko is placing greater emphasis on specialty pharmacy and complex-care services within Evernorth. The focus targets areas where healthcare costs are rising and could create growth opportunities through higher-value clinical and pharmacy capabilities. Cigna to Ramp Up Investments in Specialty Pharmacy and Complex Care
• Positive Sentiment: Cigna’s international health business announced an exclusive agreement with UnitedHealthcare Global, potentially expanding distribution and international capabilities. Cigna International agreement with UnitedHealthcare Global
• Neutral Sentiment: Analysts continue to show a generally favorable view, with Cigna receiving a consensus “Moderate Buy” rating. However, the key question is whether the new specialty-pharmacy strategy can translate into sustained earnings growth under the new CEO. Cigna consensus rating
• Negative Sentiment: Cigna reaffirmed 2026 adjusted EPS guidance of approximately $30.45, slightly below the $30.51 consensus, while setting revenue guidance at $280 billion versus an estimated $287.2 billion. The revenue shortfall may limit near-term upside despite the stronger long-term outlook. Cigna long-term targets and 2026 guidance

About Cigna Group

The Cigna Group NYSE: CI is a global health company that provides health care and related services to individuals, employers, government organizations and health plans. Its operations are primarily organized through Cigna Healthcare and Evernorth Health Services, which together address health coverage, pharmacy services, care delivery and benefit management.

Cigna Healthcare offers medical, dental, behavioral health, disability and other benefits, with a focus on employer-sponsored and individual health plans in the United States as well as international health services.